BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ in Breast and Prostate Cancer Models

• SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform
• Lead candidates Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer) completing GMP manufacturing for planned clinical trials
• $2 million National Cancer Institute (NCI) Small Business Innovative Research (SBIR) award supports manufacturing and planned clinical evaluation of Bria-PROS+
• Bria-OTS+ represents a novel, cost-effective, off-the-shelf potent next generation cancer therapy platform

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be showing evidence of strong immune system engagement inducing potent anti-cancer cell activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40^th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD. The details are listed below.

Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance
Abstract Number: 353
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
Date: Friday, November 7, 2025
Time: 12:15-1:45 PM, and 5:35-7 PM ET

“We are very excited with this opportunity to showcase the activity of our novel Bria-OTS+ platform which is designed to reinvigorate the body’s immune system to powerfully and selectively attack cancer cells while sparing normal tissues,” commented Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer.

“We will present extensive immune system activation and cytotoxicity data at the upcoming poster session on November 7, 2025. Our data further validates the promise of our personalized cancer immunotherapy platform in advancing new treatments for cancer,” stated Dr. William V. Williams, BriaCell’s President and CEO. “We look forward to evaluating these encouraging results in upcoming clinical studies of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, as we strive to bring new hope to patients with unmet medical needs.”